Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals (TLX) enters an exclusive commercial distribution agreement with NUCLIBER S.A Spain for its prostate cancer investigational imaging product, Illuccix
- Under the agreement, NUCLIBER will be the distributor and local representative for Illuccix in Spain
- Meanwhile, Telix is continuing to progress marketing authorisation applications for Illuccix in the European Union and Canada.
- Telix Pharmaceuticals is up 4.78 per cent, trading at $7.23 at 11:10 am AEDT
Telix Pharmaceuticals (TLX) has penned a distribution agreement for prostate cancer imaging in Spain.
The company entered an exclusive commercial distribution agreement with Madrid-based NUCLIBER S.A Spain for Telix’s product, Illuccix. NUCLIBER’s focus is on nuclear medicine, oncology, and non-destructive testing, offering a wide range of products.
Under the agreement, NUCLIBER will be the distributor and local representative for Illuccix in Spain.
Illuccix is Telix’s lead product for prostate cancer imaging, and has been approved by the Australian Therapeutic Goods Administration and accepted for filing by the US FDA.
In 2020, prostate cancer was the most commonly diagnosed cancer in men in Spain, with around 34,600 new cases being diagnosed. Prostate cancer was also a leading cause of cancer death in men, with almost 5800 men dying from the disease in Spain in 2020.
Telix EMEA President Richard Valeix said the company is pleased to partner with NUCLIBER ahead of its European launch of Illuccix.
“Collaborating with such an established and patient-centric leader in radiopharmaceuticals will help Telix to deliver on the promise of nuclear medicine with the ultimate aim to improve outcomes for Spanish men living with prostate cancer,” Mr Valeix said.
Meanwhile, Telix is continuing to progress marketing authorisation applications for Illuccix in the European Union and Canada.
Telix Pharmaceuticals was up 4.78 per cent, trading at $7.23 at 11:10 am AEDT.
